PDF(Pubmed)
Abstract：
OBJECTIVE: This systematic review and meta-analysis aimed to compare the effectiveness and safety of molnupiravir and sotrovimab in the treatment of patients with coronavirus disease 2019 (COVID-19).
METHODS: Cochrane Library, Web of Science, PubMed, medRxiv, and Google Scholar were systematically searched to identify relevant evidence up to December 2023. The risk of bias was assessed using the risk of bias in nonrandomized studies of interventions tool. Data were analyzed using Comprehensive Meta-Analysis (CMA).
RESULTS: Our search identified and included 13 studies involving 16166 patients. The meta-analysis revealed a significant difference between the molnupiravir and sotrovimab groups in terms of the mortality rate (odds ratio [OR] = 2.07, 95% confidence interval [CI]: 1.16, 3.70). However, no significant difference was observed between the two groups in terms of hospitalization rate (OR = 0.71, 95% CI: 0.47, 1.06), death or hospitalization rate (OR = 1.51, 95% CI: 0.81, 2.83), and intensive care unit admission (OR = 0.59, 95% CI: 0.07, 4.84). In terms of safety, molnupiravir was associated with a higher incidence of adverse events (OR = 1.67, 95% CI: 1.21, 2.30).
CONCLUSIONS: The current findings indicate that sotrovimab may be more effective than molnupiravir in reducing the mortality rate in COVID-19 patients. However, no statistical difference was observed between the two treatments for other effectiveness outcomes. The certainty of evidence for these findings was rated as low or moderate. Further research is required to provide a better comparison of these interventions in treating COVID-19 patients.
METHODS: Cochrane Library, Web of Science, PubMed, medRxiv, and Google Scholar were systematically searched to identify relevant evidence up to December 2023. The risk of bias was assessed using the risk of bias in nonrandomized studies of interventions tool. Data were analyzed using Comprehensive Meta-Analysis (CMA).
RESULTS: Our search identified and included 13 studies involving 16166 patients. The meta-analysis revealed a significant difference between the molnupiravir and sotrovimab groups in terms of the mortality rate (odds ratio [OR] = 2.07, 95% confidence interval [CI]: 1.16, 3.70). However, no significant difference was observed between the two groups in terms of hospitalization rate (OR = 0.71, 95% CI: 0.47, 1.06), death or hospitalization rate (OR = 1.51, 95% CI: 0.81, 2.83), and intensive care unit admission (OR = 0.59, 95% CI: 0.07, 4.84). In terms of safety, molnupiravir was associated with a higher incidence of adverse events (OR = 1.67, 95% CI: 1.21, 2.30).
CONCLUSIONS: The current findings indicate that sotrovimab may be more effective than molnupiravir in reducing the mortality rate in COVID-19 patients. However, no statistical difference was observed between the two treatments for other effectiveness outcomes. The certainty of evidence for these findings was rated as low or moderate. Further research is required to provide a better comparison of these interventions in treating COVID-19 patients.
摘要：
目的：本系统评价和荟萃分析旨在比较莫诺比拉韦和索特罗韦单抗治疗2019年冠状病毒病患者（COVID-19）的有效性和安全性。
方法：Cochrane图书馆，WebofScience,PubMed,medRxiv,和谷歌学者进行了系统搜索，以确定截至2023年12月的相关证据。使用干预工具的非随机研究中的偏倚风险评估偏倚风险。采用综合Meta分析(CMA)对数据进行分析。
结果：我们的搜索确定并纳入了13项研究，涉及16166名患者。荟萃分析显示，molnupiravir组和sotrovimab组之间的死亡率存在显着差异（比值比[OR]=2.07，95％置信区间[CI]：1.16，3.70）。然而,两组住院率无显著差异(OR=0.71,95%CI:0.47,1.06),死亡率或住院率(OR=1.51，95%CI：0.81，2.83)，和重症监护病房入院(OR=0.59，95%CI：0.07，4.84)。在安全方面,莫那普拉韦与较高的不良事件发生率相关(OR=1.67,95%CI:1.21,2.30)。
结论：目前的研究结果表明，sotrovimab在降低COVID-19患者死亡率方面可能比莫诺比拉韦更有效。然而,两种治疗方法的其他有效性结局无统计学差异.这些发现的证据的确定性被评为低或中等。需要进一步的研究来更好地比较这些干预措施在治疗COVID-19患者中的作用。
方法：Cochrane图书馆，WebofScience,PubMed,medRxiv,和谷歌学者进行了系统搜索，以确定截至2023年12月的相关证据。使用干预工具的非随机研究中的偏倚风险评估偏倚风险。采用综合Meta分析(CMA)对数据进行分析。
结果：我们的搜索确定并纳入了13项研究，涉及16166名患者。荟萃分析显示，molnupiravir组和sotrovimab组之间的死亡率存在显着差异（比值比[OR]=2.07，95％置信区间[CI]：1.16，3.70）。然而,两组住院率无显著差异(OR=0.71,95%CI:0.47,1.06),死亡率或住院率(OR=1.51，95%CI：0.81，2.83)，和重症监护病房入院(OR=0.59，95%CI：0.07，4.84)。在安全方面,莫那普拉韦与较高的不良事件发生率相关(OR=1.67,95%CI:1.21,2.30)。
结论：目前的研究结果表明，sotrovimab在降低COVID-19患者死亡率方面可能比莫诺比拉韦更有效。然而,两种治疗方法的其他有效性结局无统计学差异.这些发现的证据的确定性被评为低或中等。需要进一步的研究来更好地比较这些干预措施在治疗COVID-19患者中的作用。
